Prognostic value and clinical significance of long noncoding RNA CASC2 in human malignancies: a meta-analysis

Juan Cai1,*, Xiaoliang Zuo2,*, Zhiqiang Chen3,4,*, Wening Zhao1, Yiping Zhu1, Zhengxiang Zhang1, Xiaobing Ye1

1Department of Oncology, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China; 2Department of Gastrointestinal Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, China; 3Department of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China; 4Key Laboratory of Hepatobiliary Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

*These authors contributed equally to this work

Purpose: This meta-analysis aimed to assess the prognostic value of long noncoding RNA cancer susceptibility candidate 2 (CASC2) in human tumors.

Materials and methods: We searched the available databases up to December 2017. Pooled hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) were used to examine the prognostic impact of CASC2 on overall survival (OS) in patients diagnosed with malignancies.

Results: A total of eight studies with 663 cancer patients were enrolled. Our results showed that high CASC2 expression level was associated with a favorable OS (HR = 0.437, 95% CI: 0.345–0.554). The significant results were not altered by stratified analysis according to cancer type, sample size, follow-up months, and HR estimation method. A significant association of glioma tumor stage with CASC2 expression was detected (III–IV vs I–II: odds ratio = 2.126, 95% CI: 1.032–4.378). CASC2 could be used as an independent prognostic factor for OS (HR = 0.450, 95% CI: 0.336–0.602). Sensitivity analysis showed that no single study changed the pooled results significantly. Begg’s funnel plot and Egger’s test showed that no publication bias was detected.

Conclusion: High expression level of CASC2 is associated with favorable survival outcome for cancer patients, and CASC2 could be used as a prognostic predictor for cancers.

Keywords: CASC2, long noncoding RNA, prognosis, meta-analysis

Introduction
Cancer is becoming a leading cause of morbidity and mortality around the world.1 In 2015, 4,292,000 new cancer cases and 2,814,000 cancer-related deaths occurred in China.2 The 5-year survival rate of most cancer patients remains dismal due to lack of effective diagnostic and therapeutic tools.3 Previous studies showed that many genes are closely related to cancer progression; however, the complex molecular mechanisms have not been completely elucidated.4,5 Therefore, developing a more effective diagnostic and treatment method is an imperative task.

In recent years, increasing evidence has identified that tumorigenesis is associated with long noncoding RNAs (lncRNAs, >200 nucleotides in length).6 LncRNAs have been acknowledged as indispensable players in chromatin remodeling, gene regulation, and epigenetic modification at the transcriptional and posttranscriptional levels.7 In addition, lncRNAs play an important role in various biological processes, including cell proliferation, differentiation, apoptosis, and invasion.8,9 LncRNAs are less conserved and unable to encode proteins. Given that lncRNAs have been verified as
crucial molecules in various cancers, they could be potential biomarkers for cancer prognosis.

Cancer susceptibility candidate 2 (CASC2), located at chromosome 10q26, is an lncRNA that functions as a tumor suppressor. Mounting evidence has demonstrated that CASC2 plays diverse roles in different cancers, including endometrial cancer, cervical cancer, nonsmall cell–lung cancer, renal cell carcinoma, gliomas, and digestive system cancers. Several studies indicated that overexpression of CASC2 inhibits cancer cell proliferation, migration, and invasion. A significant decrease in CASC2 expression is associated with poor prognosis of cancer patients. With a growing number of studies demonstrating the involvement of CASC2 in tumorigenesis, the detection of CASC2 level in cancer patients is valuable for outcome prediction.

However, previous studies reported that the relationship between CASC2 and malignant tumors remains insufficient due to limitations in sample size and discrete outcomes. In view of the aforementioned facts, we comprehensively collected related publications and conducted this study to address the association of CASC2 expression with patient survival and clinicopathological characteristics. Thus, we analyzed all relevant studies to investigate whether CASC2 could serve as an effective prognostic marker in human cancer.

Materials and methods

Search strategy

In order to identify relevant published studies, electronic searches of PubMed, Web of Science, EMBASE, Cochrane Library, Google Scholar, and Chinese National Knowledge Infrastructure database were done for the query “CASC2 or CASC2a” and “cancer or carcinoma or tumor or tumor or neoplasm or malignancy.” An additional hand search of references of original or review articles on this topic was performed. The literature search included all relevant studies published until December 2017 for which an abstract or manuscript was available.

Inclusion criteria and exclusion criteria

Inclusion criteria for the meta-analysis were: 1) the study explored any type of human tumors; 2) the relationship between CASC2 and clinical prognosis was investigated; and 3) the study provided usable data for estimating hazard ratios (HRs) and 95% confidence intervals (CIs) for survival outcomes. The exclusion criteria for articles were: 1) studies without complete data; 2) duplicate publications; and 3) animal studies, case reports, and reviews.

Data extraction

Titles and abstracts of potentially relevant articles were screened by two independent investigators (CJ and CZQ), and full-text manuscripts meeting the initial screening criteria were obtained. The investigators independently examined all full-text articles for inclusion in the review; any discrepancies were discussed by the investigators. If they were unable to reach consensus, a third investigator (ZXL) was consulted. Standardized data extraction tables were created, and data extraction was completed by CZQ and checked by ZXL for accuracy. Information including the first author’s name, year of publication, cancer type, tumor stage, sample size, cutoff value, CASC2 detection method, preoperative treatment, follow-up months, survival analysis, and HRs with the corresponding 95% CIs was extracted. If HRs and their 95% CIs could not be obtained directly from publications, they were extracted from Kaplan–Meier curves by using the Engauge Digitizer Version 4.1 (http://markumitchell.github.io/engauge-digitizer). The quality of the literature was evaluated according to the Newcastle–Ottawa Scale (NOS), and the studies with NOS score ≥7 were considered to be high quality.

Statistical analysis

All meta-analyses were performed with Stata software version 12.0 (StataCorp LP, College Station, TX, USA). HRs with the corresponding 95% CIs were used to estimate the strength of the relationship between CASC2 and clinical prognosis of the cancer patients. Pooled odds ratios (ORs) with 95% CIs were used to assess the association of lncRNA expression with clinicopathological characteristics. Heterogeneity between studies was quantified by chi-squared test and I² statistics. A chi-squared test of p<0.10 or I²>50% indicated heterogeneity across the studies. If the heterogeneity was not significant, we used a fixed effect model to investigate the pooled HRs. Random effect model was used to summarize the statistical synthesis if between-study heterogeneity was substantial. Subgroup analyses were conducted according to cancer type, sample size, follow-up months, and HR estimation method. Sensitivity analysis was performed by sequentially omitting individual study to guarantee the robustness of the results. Begg’s funnel plot and Egger’s test were employed to evaluate the risk of publication bias. p<0.05 was considered as statistically significant.

Results

Study characteristics

The search strategy retrieved 328 potentially relevant studies. Based on the screening criteria, eight eligible studies with 663 patients were enrolled in the current meta-analysis.
The flowchart of this study selection was concluded and shown in Figure 1. Study characteristics of these eight studies were summarized in Table 1. All studies were published in recent 2 years, suggesting that the prognostic value of CASC2 is a novel field of research. Of the enrolled studies, three focused on digestive system malignancies, including pancreatic cancer, gastric cancer, and hepatocellular carcinoma (HCC), while the other five studies on nondigestive system malignancies (thyroid carcinoma, glioma, and lung cancer). Eight studies were for overall survival (OS) and one for disease-free survival. The maximum and minimum sample size were 110 and 57, respectively. The follow-up time ranged between 32 and 70 months.

**Association of CASC2 with OS**

A total of eight studies assessed the HRs for OS. No heterogeneity was found among the studies (chi-squared=6.26, df=7, \( p=0.509, I^2=0\)%), thus a fixed effect model was employed to pool the association of CASC2 expression with OS of multiple malignancies. As illustrated in Figure 2 and Table 2, it was indicated that increased CASC2 expression predicted a favorable outcome for OS of cancer patients (pooled HR=0.437, 95% CI: 0.345–0.554).

Subsequent stratified analyses were performed according to cancer type, sample size, follow-up months, and HR estimation method (Figure 3A–D and Table 2). A significant relationship between CASC2 overexpression and a favorable OS was observed in patients with digestive system cancer (HR=0.399, 95% CI: 0.275–0.580) and nondigestive system cancer patients (HR=0.464, 95% CI: 0.343–0.630). In the analysis stratified by sample size, CASC2 was found to be significantly correlated to patient survival in studies with sample size less than the median value of 74 (HR=0.410, 95% CI: 0.296–0.568) and >74 (HR=0.470, 95% CI: 0.333–0.661). There was a significant correlation between CASC2 expression level and patient survival outcome in studies with follow-up time >60 months (HR=0.448, 95% CI: 0.322–0.623) and <60 months (HR=0.426, 95% CI: 0.304–0.597). In addition, stratified analysis on HR estimation method revealed a statistical significance in both the subgroups (indirectly: HR=0.414, 95% CI: 0.277–0.620; directly: HR=0.450, 95% CI: 0.336–0.602).

---

**Figure 1** Flowchart of the study search and selection in this meta-analysis.
Table 1 Characteristics of the studies included in the meta-analysis (n=8)

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Cancer type</th>
<th>Tumor stage</th>
<th>Sample size</th>
<th>Cutoff value</th>
<th>Laboratory method</th>
<th>HR Follow-up months</th>
<th>Outcome measures</th>
<th>HR (95% CI)</th>
<th>HR estimation method</th>
<th>NOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhou et al</td>
<td>2017</td>
<td>GC</td>
<td>I–IV</td>
<td>69</td>
<td>Median</td>
<td>qRT-PCR</td>
<td>No 70</td>
<td>OS</td>
<td>0.37 (0.15–0.94)</td>
<td>Indirectly</td>
<td>7</td>
</tr>
<tr>
<td>Yu et al</td>
<td>2017</td>
<td>Pancreatic cancer</td>
<td>I–IV</td>
<td>110</td>
<td>Median</td>
<td>qRT-PCR</td>
<td>NA 48</td>
<td>OS</td>
<td>0.409 (0.241–0.691)</td>
<td>Directly</td>
<td>8</td>
</tr>
<tr>
<td>Xiong et al</td>
<td>2017</td>
<td>Thyroid carcinoma</td>
<td>I–IV</td>
<td>86</td>
<td>Mean</td>
<td>qRT-PCR</td>
<td>No 32</td>
<td>OS</td>
<td>0.105 (0.11–1.045)</td>
<td>Univariate, multivariate</td>
<td>8</td>
</tr>
<tr>
<td>Wang et al</td>
<td>2017</td>
<td>Glioma</td>
<td>I–IV</td>
<td>47</td>
<td>Median</td>
<td>qRT-PCR</td>
<td>No 60</td>
<td>OS</td>
<td>0.316 (0.170–0.536)</td>
<td>Directly</td>
<td>7</td>
</tr>
<tr>
<td>Wang et al</td>
<td>2017</td>
<td>Lung adenocarcinoma</td>
<td>I–IV</td>
<td>63</td>
<td>Median</td>
<td>qRT-PCR</td>
<td>No 60</td>
<td>OS</td>
<td>0.46 (0.24–0.88)</td>
<td>Directly</td>
<td>8</td>
</tr>
<tr>
<td>Wang et al</td>
<td>2017</td>
<td>HCC</td>
<td>I–IV</td>
<td>75</td>
<td>Median</td>
<td>qRT-PCR</td>
<td>No 36</td>
<td>OS</td>
<td>0.40 (0.23–0.717)</td>
<td>Directly</td>
<td>8</td>
</tr>
<tr>
<td>Liao et al</td>
<td>2017</td>
<td>Glioma</td>
<td>I–IV</td>
<td>32</td>
<td>Median</td>
<td>qRT-PCR</td>
<td>NA 36</td>
<td>OS</td>
<td>0.53 (0.28–0.985)</td>
<td>Directly</td>
<td>8</td>
</tr>
<tr>
<td>He et al</td>
<td>2016</td>
<td>NSCLC</td>
<td>I–IV</td>
<td>60</td>
<td>Median</td>
<td>qRT-PCR</td>
<td>No 60</td>
<td>OS</td>
<td>0.27 (0.09–0.768)</td>
<td>Directly</td>
<td>7</td>
</tr>
</tbody>
</table>

Abbreviations: GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, nonsmall cell–lung cancer; PT, preoperative treatment; NA, not available; OS, overall survival; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; NOS, Newcastle–Ottawa Scale; qRT-PCR, quantitative real time polymerase chain reaction.

To investigate the robustness of our pooled estimates, we performed sensitivity analysis by omitting one study each time. The sensitivity analysis showed that no individual study altered the pooled results significantly, confirming the stability of our data (Figure 4).

Independent prognostic value of CASC2

Cox proportional multivariate model was used in five studies to assess the role of CASC2 as an independent prognostic factor for various malignancies. As shown in Figure 5, it was revealed that CASC2 was an independent prognostic factor for OS in tumor patients (pooled HR=0.450, 95% CI: 0.336–0.602). No statistically significant heterogeneity was found across these studies (chi-squared=6.02, df=4, p=0.198, $I^2=33.6%$).

Correlation between CASC2 and clinicopathological features

A total of six studies investigated the correlation between CASC2 expression and clinicopathological features of human tumors. Two studies focused on glioma, two on HCC, and two on lung cancer. A significant association of glioma tumor stage with CASC2 expression was detected (III–IV vs I–II: OR=2.126, 95% CI: 1.032–4.378). However, the pooled estimates showed that CASC2 expression was not correlated to other clinicopathological features in glioma, HCC, and lung cancer (Table 3).

Publication bias

Begg’s funnel plot and Egger’s test were used to assess the potential bias in the available literature. The shape of funnel plots showed no evidence of asymmetry (Figure 6). In addition, Egger’s test indicated that there was no significant publication bias ($p=0.332$).

Discussion

Recent genome studies have demonstrated that dysfunctional IncRNAs are involved in tumor occurrence and progression. Considered as novel molecular biomarkers, IncRNAs may be used for the prediction of cancer prognosis. Previous studies have shown that CASC2 expression level is downregulated in many cancers, including nonsmall cell–lung cancer, gliomas, gynecological malignant tumor, urinary system cancers, and digestive tract tumors. To assess the prognostic role of CASC2 in various human cancers, we implemented this comprehensive meta-analysis. Our statistically significant results of pooled estimates suggested that CASC2 could be used as a prognostic candidate for most human malignancies.
Systematic analysis of the relationship between CASC2 overexpression and a favorable OS was observed, suggesting that CASC2 may be used as a predictor for OS of cancer patients. Subgroup analyses, including tumor type, sample size, follow-up time, and HR estimation method, showed that the value of CASC2 for OS existed in all subgroups. Cox
Figure 3 Forest plots of the subgroup analyses evaluating HRs of CASC2 for overall survival by the factors of cancer type (A), sample size (B), follow-up months (C), and HR estimation method (D).

Abbreviations: HR, hazard ratio; CI, confidence interval; CASC2, cancer susceptibility candidate 2.

Figure 4 Sensitivity analysis of the effect of the individual study on the pooled HRs for the correlation between CASC2 and overall survival.

Abbreviations: HR, hazard ratio; CI, confidence interval; CASC2, cancer susceptibility candidate 2.
Table 3 Results of the association of CASC2 expression with clinicopathological features

<table>
<thead>
<tr>
<th>Clinicopathological features</th>
<th>No. of studies</th>
<th>Pooled OR (95% CI)</th>
<th>p-value</th>
<th>Heterogeneity I² (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glioma</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (≥45 vs &lt;45 years)</td>
<td>2</td>
<td>0.813 (0.425–1.555)</td>
<td>0.797</td>
<td>0</td>
<td>0.531</td>
</tr>
<tr>
<td>Gender (male vs female)</td>
<td>2</td>
<td>1.059 (0.558–2.011)</td>
<td>0.712</td>
<td>0</td>
<td>0.860</td>
</tr>
<tr>
<td>Tumor stage (III–IV vs I–II)</td>
<td>2</td>
<td>2.126 (1.032–4.378)</td>
<td>0.041</td>
<td>0</td>
<td>0.936</td>
</tr>
<tr>
<td><strong>HCC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (≥50 vs &lt;50 years)</td>
<td>2</td>
<td>1.023 (0.579–1.808)</td>
<td>0.938</td>
<td>0</td>
<td>0.843</td>
</tr>
<tr>
<td>Gender (male vs female)</td>
<td>2</td>
<td>0.940 (0.557–1.587)</td>
<td>0.816</td>
<td>0</td>
<td>0.864</td>
</tr>
<tr>
<td>Tumor number (multiple vs single)</td>
<td>2</td>
<td>1.453 (0.574–3.679)</td>
<td>0.431</td>
<td>22.40</td>
<td>0.257</td>
</tr>
<tr>
<td>Tumor size (≥5 vs &lt;5 cm)</td>
<td>2</td>
<td>1.394 (0.755–2.574)</td>
<td>0.288</td>
<td>0</td>
<td>0.869</td>
</tr>
<tr>
<td>TNM stage (III–IV vs I–II)</td>
<td>2</td>
<td>1.955 (0.581–6.576)</td>
<td>0.279</td>
<td>61.40</td>
<td>0.107</td>
</tr>
<tr>
<td>AFP (ng/mL) (≥400 vs &lt;400)</td>
<td>2</td>
<td>1.319 (0.716–2.431)</td>
<td>0.374</td>
<td>0</td>
<td>0.394</td>
</tr>
<tr>
<td>HBV (yes vs no)</td>
<td>2</td>
<td>1.059 (0.622–1.804)</td>
<td>0.832</td>
<td>0</td>
<td>0.640</td>
</tr>
<tr>
<td><strong>Lung cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender (male vs female)</td>
<td>2</td>
<td>1.017 (0.559–1.849)</td>
<td>0.956</td>
<td>0</td>
<td>0.485</td>
</tr>
<tr>
<td>TNM stage (III–IV vs I–II)</td>
<td>2</td>
<td>1.881 (0.960–3.688)</td>
<td>0.066</td>
<td>0</td>
<td>0.873</td>
</tr>
<tr>
<td>Lymph node metastasis (positive vs negative)</td>
<td>2</td>
<td>1.300 (0.740–2.285)</td>
<td>0.361</td>
<td>0</td>
<td>0.541</td>
</tr>
<tr>
<td>Tumor size (≥3 vs &lt;3 cm)</td>
<td>2</td>
<td>1.660 (0.939–2.935)</td>
<td>0.081</td>
<td>0</td>
<td>0.450</td>
</tr>
</tbody>
</table>

**Abbreviations:** OR, odds ratio; CI, confidence interval; HCC, hepatocellular carcinoma; TNM, tumor-node metastasis; AFP, α-fetoprotein; HBV, hepatitis B virus; CASC2, cancer susceptibility candidate 2.
proportional multivariate model indicated that CASC2 was an independent prognostic factor for OS in cancer patients. Furthermore, we found that advanced tumor stage was associated with downregulated CASC2 expression in glioma. Our data also indicated that there was no correlation between CASC2 and other clinicopathological features, including age, gender, tumor size, and lymph node metastasis. Begg’s funnel plot and Egger’s test revealed no significant publication bias. Further sensitivity analysis suggested that our results were robust.

CASC2 is a novel lncRNA involved in cancer progression and correlated to tumor prognosis. Three different mRNAs, CASC2a, CASC2b, and CASC2c, originated from alternative splicing of the five exons of CASC2.11 Previous studies have indicated that CASC2a was downregulated in cancer tissue specimens and cell lines.18,21 Most studies focused on CASC2a, whereas Liu et al31 investigated the function of CASC2c. The present meta-analysis evaluated the prognostic value of CASC2a in human malignancies; therefore, we ruled out the study on CASC2c from our analysis.

A recent review has summarized the potential functions and pathways associated with CASC2.32 The study has shown that CASC2 regulates multiple key regulators in cancer-associated signaling transduction network and acts as a powerful tumor suppressor. By sponging a panel of microRNAs or other elements, CASC2 modulates several important signaling pathways, including the PI3K/Akt, NK-κB, MAPK, Wnt/β-catenin, and Jak/Stat3 signaling. Cao et al29 reported that the expression level of CASC2 in renal cell carcinoma is significantly lower than that in normal tissue. Regulated by miR-21, CASC2 suppresses the development of renal cell carcinoma cells. In colorectal cancer, CASC2 increases protein inhibitor of activated STAT 3 expression level by functioning as a competing endogenous RNA for miR-18a, resulting in enhanced cancer cell proliferation.6 CASC2 regulates MAPK signaling pathway to suppress gastric cancer33 and HCC34 cells in vivo and in vitro. Moreover, CASC2a is associated with the risk of recurrence among patients undergoing radical cystectomy, indicating that CASC2a could act as a survival predictor and potential therapeutic target in bladder cancer.35 It has also been reported that overexpression of CASC2 reduces bladder cancer cell growth via suppressing Wnt/β-catenin pathway.36 In addition, CASC2 increases the sensitivity of chemotherapeutic drugs, such as cisplatin and docetaxel. CASC2 overexpression could sensitize cisplatin-resistant cervical cancer cell to cisplatin through targeting miR-21 and miR-181a and inhibiting PI3K/Akt pathway.13,26 Gao et al36 reported that CASC2 competes with SPRY2 for miR-183 binding to enhance the sensitivity of prostate cancer cells to docetaxel via SPRY2 downstream ERK signaling pathway. Hence, CASC2 could exert a strong antitumor effect and function as a promising prognostic factor for patients diagnosed with malignancies.

Despite our efforts to make a comprehensive study, this meta-analysis still has several limitations. First, the sample size is relatively small. Given the limited number of literature pertaining to the prognostic role of CASC2 in a single type of tumor, we were unable to pool the results in one type of malignancy. To handle this issue, we attempted to analyze the role of CASC2 in digestive system and nondigestive systems.
system cancers and confirmed the prognostic significance of CASC2 in both the subgroups. Second, the prognostic value of CASC2 is a relatively novel field of research, and the included studies were published in recent 2 years. All enrolled patients were from China, which means our results might not be applied to different ethnicities and regions. Therefore, more large-scale studies are duly warranted to further verify the prognostic value of CASC2 in different ethnicities. Third, the cutoff value for CASC2 expression varied across different studies, since a consensus value was hard to reach. Fourth, some of the HRs were extracted indirectly through reconstructing Kaplan–Meier survival curves. Fifth, the data collection may be incomplete because we only retrieve literature from Chinese and English databases. Therefore, it might be possible that our meta-analysis overestimated the predictive significance of CASC2 in cancer patients.

**Conclusion**

In summary, our results showed that downregulation of CASC2 expression is associated with poor OS in various cancers. Accordingly, CASC2 expression might be used as a novel biomarker to predict the prognosis of cancer patients. Thus, more clinical studies investigating more types of cancer with larger sample size are needed to further clarify the role of CASC2 in cancer prognosis.

**Acknowledgment**

This study was funded by the Natural Science Research of Anhui Education Department Key Project (No. KJ2018A0246).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**